Merck KGaA has said that "the growth and expansion phase" of its strategy is "well on track," and the aim of additional annual sales of €2bn by 2022 from new therapies such as Mavenclad and Bavencio is an achievable target.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?